You are here

Article Text

Article menu
Download PDFPDF
Letter
Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran
  1. M Arai
  1. Department of Neurology, Seirei Mikatahara General Hospital, Mikatahara-cho 3453, Hamamatsu, Shizuoka 433-8558, Japan
  1. Correspondence to:
 Dr M Arai;
 arai-m{at}sis.seirei.or.jp

https://doi.org/10.1136/jnnp.74.1.137

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Milnacipran is a new class of antidepressant, a dual serotonin (5-HT) and noradrenaline (norepinephrine) reuptake inhibitor (SNRI).1 It shows no affinity for neurotransmitter receptors.1 The use of selective serotonin reuptake inhibitor (SSRI) has been associated with the occurrence and worsening of parkinsonism.2,3 However, SNRI induced parkinsonism has not been reported. A case is reported here in which severe parkinsonism occurred in association with the use of milnacipran.

    A 83 year old woman was prescribed 200 mg of etidronate disodium once daily, and 0.25 μg of calcitriol for osteoporosis. In July 2001, she was prescribed 15 mg of milnacipran twice daily to alleviate her depressive …

    View Full Text

    Footnotes

    • Competing interests: none declared.